Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Antibodies in Drug Discovery

John Castle's Biography

John Castle, Executive Director, Vaccine Research and Translational Medicine, Agenus Switzerland Inc.

We’re defining a new therapeutic paradigm where NGS, bioinformatics, and immunomics are used to generate individualized therapies manufactured on-demand for patients. Originally trained in physics, I moved to Rosetta Inpharmatics, later part of Merck Sharp and Dohme (MSD), where I contributed to the development of novel computational biology, lab and genomic platforms for novel drug targets and biomarkers. In Mainz, Germany, I built a genomics and computational immunology department focused on novel cancer immunotherapies, resulting in first-in-man clinical trials of individualized neoantigen vaccines. At Agenus, we’re pushing the boundaries to rapidly design and manufacture custom-made vaccines for patients and combine the vaccines with immunomodulatory antibodies.

John Castle Image

Integration of High Throughput ‘Omic Platforms into Antibody Discovery

Wednesday, 10 February 2016 at 15:30

Add to Calendar ▼2016-02-10 15:30:002016-02-10 16:30:00Europe/LondonIntegration of High Throughput ‘Omic Platforms into Antibody DiscoveryAntibodies in Drug Discovery in Cambridge, UKCambridge,

We use ‘omics technologies to identify and develop novel immune cell receptors. Our workflow harnesses cellular display, next-generation sequencing, mass-spec, bio data, biostatistics, and computational immunology from discovery to regulatory filing.

Add to Calendar ▼2016-02-09 00:00:002016-02-10 00:00:00Europe/LondonAntibodies in Drug DiscoveryAntibodies in Drug Discovery in Cambridge, UKCambridge,